(AOF) – The Boards of Directors of Biosynex, specialized in the design, distribution and marketing of in vitro diagnostic devices, and of Theradiag, specialized in in vitro diagnostics, unanimously approved the principle of a proposed merger by absorption of Theradiag by Biosynex. This project follows the public acquisition offer made by Biosynex for the securities of its partner, the announcement of the final results of which took place on February 2, 2023. To date, Biosynex holds 73.14% of the capital and 72.99 % of Theradiag voting rights.
The project is part of a rationalization process for the Biosynex group with a desire to “create a world leader in biotherapy monitoring”.
“The Merger Project with Theradiag will significantly advance our mission of developing, manufacturing and marketing biotherapy monitoring tests,” said Larry Abensur, CEO of Biosynex. “The rationalization of our activities will also make it possible to generate substantial savings thanks to a more integrated organization.”